Джозеф Меркола - Кето-навигатор

37. Corbin KD, Zeisel SH. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol . 2012 Mar; 28 (2): 159–165.

38. Nguyen LN, Ma D, Shui G, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature . 2014 May 22; 509 (7501): 503–506.

39. Alakbarzade V, Hameed A, Quek DQ, et al. A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter MFSD2A causes a non-lethal microcephaly syndrome. Nat Genet . 2015 Jul; 47 (7): 814–817.

40. Guemez-Gamboa A, Nguyen LN, Yang H, et al. Inactivating mutations in MFSD2A, required for omega-3 fatty acid transport in brain, cause a lethal microcephaly syndrome. Nat Genet . 2015 Jul; 47 (7): 809–813.

41. MSC labelled Aker Biomarine krill products are from a sustainable and wellmanager fishery [Internet. Marine Stewardship Counci. 2018 Mar 27. Доступно по ссылке http://www.msc.org/newsroom/news/msc-labelled-aker-biomarine-krillproducts-are-from-a-sustainable-and-well-managed-fishery.

42. Ulven SM, Kirkhus B, Lamglait A, et al. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids. 2011 Jan; 46 (1): 37–46.

43. Krill oil. Monograph. Altern Med Rev . 2010 Apr; 15 (1): 84–86.

44. Maki KC, Reeves MS, Farmer M, et al. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res . 2009 Sep; 29 (9): 609–615.

45. Deutsch L. Evaluation of the effect of Neptune Krill Oil on chronic inflammation and arthritic symptoms. J Am Coll Nutr . 2007 Feb; 26 (1): 39–48.

46. Sampalis F, Bunea R, Pelland MF, et al. Evaluation of the effects of Neptune Krill Oil on the management of premenstrual syndrome and dysmenorrhea. Altern Med Rev . 2003 May; 8 (2): 171–179.

47. Gamma-linolenic acid (GLA). Monograph. Altern Med Rev . 2004 Mar; 9 (1): 70–78.

48. Там же.

49. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med .1993 Nov 1; 119 (9): 86–873.

50. Zurier RB, Rossetti RG, Jacobson EW, et al. gamma-Linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis Rheum .1996 Nov; 39 (11): 1808–1817.

51. Gamma-linolenic acid (GLA). Monograph. Altern Med Rev . 2004 Mar; 9 (1): 70–78.

52. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with blackcurrant seed oil. Br J Rheumatol . 1994 Sep; 33 (9): 847–852.

53. Melnik BC, Plewig G. Is the origin of atopy linked to deficient conversion of omega-6-fatty acids to prostaglandin E1? J Am Acad Dermatol . 1989 Sep; 21 (3 Pt 1): 557–563.

54. Morse PF, Horrobin DF, Manku MS, et al. Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema. Relationship between plasma essential fatty acid changes and clinical response. Br J Dermatol . 1989 Jul; 121 (1): 75–90.

55. Horrobin DF. Nutritional and medical importance of gamma-linolenic acid. Prog Lipid Res . 1992; 31 (2): 163–194.

56. Hansen AE. Essential fatty acids and infant nutrition; Borden award address. Pediatrics. 1958 Mar; 21 (3): 494–501.

57. Kruger MC, Coetzer H, de Winter R, et al. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. Aging (Milano) . 1998 Oct; 10 (5): 385–394.

58. Barabino S, Rolando M, Camicione P, et al. Systemic linoleic and gammalinolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea . 2003 Mar; 22 (2): 97–101.

59. Surette ME, Stull D, Lindemann J. The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients. Curr Med Res Opin . 2008 Feb; 24 (2): 559–567.

60. Brush MG, Watson SJ, Horrobin DF, et al. Abnormal essential fatty acid levels in plasma of women with premenstrual syndrome. Am J Obstet Gynecol . 1984 Oct; 150 (4): 363–366.

61. Arnold LE, Pinkham SM, Votolato N. Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder? J Child Adolesc Psychopharmacol . 2000 Summer; 10 (2): 111–117.

62. Guillaume D, Charrouf Z. Argan oil. Monograph. Altern Med Rev . 2011 Sep; 16 (3): 275–279.

63. Charrouf Z, Guillaume D. Should the amazigh diet (regular and moderate arganoil consumption) have a beneficial impact on human health? Crit Rev Food Sci Nutr . 2010 May; 50 (5): 473–477.

64. Guillaume D, Charrouf Z. Argan oil. Monograph. Altern Med Rev . 2011 Sep; 16 (3): 275–279.

65. Там же.

66. Harhar H, Gharby S, Kartah B, et al. Influence of argan kernel roasting-time on virgin argan oil composition and oxidative stability. Plant Foods Hum Nutr . 2011 Jan; 66 (2): 163–168.

67. Guillaume D, Charrouf Z. Argan oil. Monograph. Altern Med Rev . 2011 Sep; 16 (3): 275–279.

68. Там же.

69. Dobrev H. Clinical and instrumental study of the efficacy of a new sebum control cream. J Cosmet Dermatol . 2007 Jun; 6 (2): 113–118.

70. Berrougui H, Ettaib A, Herrera Gonzalez MD, et al. Hypolipidemic and hypocholesterolemic effect of argan oil (Argania spinosa L.) in Meriones shawi rats. J Ethnopharmacol . 2003 Nov; 89 (1): 15–18.

71. Derouiche A, Cherki M, Drissi A, et al. Nutritional intervention study with argan oil in man: effects on lipids and apolipoproteins. Ann Nutr Metab .2005 MayJun; 49 (3): 196–201.

72. Berrougui H, Cloutier M, Isabelle M, et al. Phenolic-extract from argan oil (Argania spinosa L.) inhibits human low-density lipoprotein (LDL) oxidation and enhances cholesterol efflux from human THP-1 macrophages. Atherosclerosis. 2006 Feb; 184 (2): 389–396.

73. Cherki M, Derouiche A, Drissi A, et al. Consumption of argan oil may have an antiatherogenic effect by improving paraoxonase activities and antioxidant status: Intervention study in healthy men. Nutr Metab Cardiovasc Dis . 2005 Oct; 15 (5): 352–360.

74. Ould Mohamedou MM, Zouirech K, El Messal M, et al. Argan oil exerts an antiatherogenic effect by improving lipids and susceptibility of LDL to oxidation in type 2 diabetes patients. Int J Endocrinol . 2011; 2011: 747835.

75. Там же.

76. Haimeur A, Messaouri H, Ulmann L, et al. Argan oil prevents prothrombotic complications by lowering lipid levels and platelet aggregation, enhancing oxidative status in dyslipidemic patients from the area of Rabat (Morocco). Lipids Health Dis . 2013; 12: 107.

77. Там же.

78. Mekhfi H, Belmekki F, Ziyyat A, et al. Antithrombotic activity of argan oil: an in vivo experimental study. Nutrition. 2012 Sep; 28 (9): 937–941.

79. El Midaoui A, Haddad Y, Couture R. Beneficial effects of argan oil on blood pressure, insulin resistance, and oxidative stress in rat. Nutrition . 2016 Oct; 32 (10): 1132–1137.

80. Bellahcen S, Hakkou Z, Ziyyat A, et al. Antidiabetic and antihypertensive effect of Virgin Argan Oil in model of neonatal streptozotocin-induced diabetic and l-nitroarginine methylester (l-NAME) hypertensive rats. J. Complement Integr Med . 2013 Jul 6; 10.

81. Berrougui H, Alvarez de Sotomayor M, Perez-Guerrero C, et al. Argan (Argania spinosa) oil lowers blood pressure and improves endothelial dysfunction in spontaneously hypertensive rats. Br J Nutr . 2004 Dec; 92 (6): 921–929.